L-NIL
Based on 10 publication(s) in Google Scholar
L-NIL is an inducible NO synthase inhibitor, with an IC50 of 3.3 μM for miNOS.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.82%
- No. CAS: 53774-63-3
- Fòrmula: C8H17N3O2
- Peso molecular:187.24
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-18731
1400W Dihydrochloride -
HY-18729A
L-NAME hydrochloride -
HY-12119
GW274150 -
HY-121526
S-Nitroso-N-acetyl-DL-penicillamine -
HY-100986
L-NIO dihydrochloride -
HY-136278
DETA NONOate -
HY-18732A
L-NMMA acetate -
HY-B0215
Acetylcysteine -
HY-B1581A
L-Canavanine sulfate -
HY-118700
2-Iminobiotin -
HY-101175
3-Bromo-7-nitroindazole -
HY-102015
6-Biopterin
Publications Citing Use of MedChemExpress (MCE) L-NIL
More- Nat Biomed Eng. 2023 Mar;7(3):281-297. [Abstract]
- Nat Commun. 2025 Jul 1;16(1):5547. [Abstract]
- J Adv Res. 2023 Jan:43:175-186. [Abstract]
- Sci Transl Med. 2025 May 21;17(799):eadn7527. [Abstract]
- Cancer Lett. 2023 Aug 28:570:216330. [Abstract]
- Free Radic Biol Med. 2023 May 1:200:73-86. [Abstract]
- J Agric Food Chem. 2024 May 29;72(21):12156-12170. [Abstract]
- Exp Eye Res. 2024 Jun:243:109886. [Abstract]
- Biochem Biophys Res Commun. 2024 Nov 19:734:150589. [Abstract]
- bioRxiv. 2026 Jun 13:2026.06.12.731980. [Abstract]
Customer Validation & Images
-
WB
Actividad biológica
Descripciòn
IC50 & Target
|
iNOS |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DLD-1 | IC50 |
0.13 μM
Compound: 3
|
Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by inducible NOS (i NOS) from human DLD-1 cells
Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by inducible NOS (i NOS) from human DLD-1 cells
|
[PMID: 11327580] |
| DLD-1 | IC50 |
470 mM
Compound: 3
|
Inhibitory concentration against nitric oxide synthesis in intact DLD-1 cells
Inhibitory concentration against nitric oxide synthesis in intact DLD-1 cells
|
[PMID: 11327580] |
| DLD-1 | IC50 |
2.8 μM
Compound: 3
|
Inhibitory activity against synthesis of inducible nitric oxide synthase by DLD-1 cells
Inhibitory activity against synthesis of inducible nitric oxide synthase by DLD-1 cells
|
[PMID: 12620067] |
| DLD-1 | IC50 |
280 nM
Compound: 1
|
Inhibition of human iNOS expressed in human DLD1 cells after 1 hr
Inhibition of human iNOS expressed in human DLD1 cells after 1 hr
|
[PMID: 18024030] |
| DLD-1 | IC50 |
31 μM
Compound: 1
|
Inhibition of cytokine-induced iNOS activity in human DLD1 cells after 24 hrs
Inhibition of cytokine-induced iNOS activity in human DLD1 cells after 24 hrs
|
[PMID: 18024030] |
| HUVEC | IC50 |
2.4 μM
Compound: 3
|
Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by endothelial NOS (e NOS) from HUVEC cells
Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by endothelial NOS (e NOS) from HUVEC cells
|
[PMID: 11327580] |
| RAW264.7 | IC50 |
>200 μM
Compound: L-NIL
|
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells by Griess method
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells by Griess method
|
[PMID: 14510614] |
| RAW264.7 | IC50 |
18.6 μM
Compound: L-NIL
|
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method
|
[PMID: 14510614] |
| RAW264.7 | IC50 |
20.14 μM
Compound: L-NIL
|
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
|
[PMID: 24360561] |
| RAW264.7 | IC50 |
15.8 μM
Compound: L-NIL
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay
|
[PMID: 25666824] |
| RAW264.7 | IC50 |
7.5 μM
Compound: L-NIL
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
|
[PMID: 27588583] |
| RAW264.7 | IC50 |
28.29 μM
Compound: L-NIL
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay
|
[PMID: 29102229] |
| RAW264.7 | IC50 |
15.8 μM
Compound: L-NIL
|
Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells after 24 hrs by Griess assay
Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells after 24 hrs by Griess assay
|
[PMID: 29799195] |
| RAW264.7 | IC50 |
1.55 μM
Compound: NIL
|
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay
|
[PMID: 29932657] |
| RAW264.7 | IC50 |
7 μM
Compound: L-Nil
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess reagent based colorimetric method
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess reagent based colorimetric method
|
[PMID: 30724564] |
| Sf9 | IC50 |
2500 nM
Compound: 1
|
Inhibition of human eNOS expressed in insect SF9 cells after 1 hr
Inhibition of human eNOS expressed in insect SF9 cells after 1 hr
|
[PMID: 18024030] |
| Sf9 | IC50 |
6 μM
Compound: 1
|
Inhibition of human nNOS expressed in insect SF9 cells after 1 hr
Inhibition of human nNOS expressed in insect SF9 cells after 1 hr
|
[PMID: 18024030] |
In Vitro
L-NIL produces a concentration-dependent inhibition of both the mouse inducible NOS (miNOS) and the rat brain constitutive NOS (rcNOS) and is considerably more potent for miNOS. The IC50 values for L-NIL with miNOS and rcNOS are 3.3 and 92 pM, respectively, indicating that L-NIL is 28-fold more selective for miNOS. In addition, L-NIL has approximately 6-fold greater potency for miNOS than either L-NMA or L-NNA[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Balb/c (20-25 g)[1].
-
Dosage:10 and 30 mg/kg.
-
Administration:Intraperitoneally at the end of CLP and at 6 h after sepsis induction.
-
Result:Led to a negligible increase in plasma NGAL compared to sham mice.
Led to a significant decrease in both TLR4 and IL1β protein contents and clusterin transcript.
Showed an increase in NFAT5 mRNA levels, as compared with mice treated with vehicle.
Promoted a decrease in AR protein expression, as compared with animals treated with vehicle.
Chemical Information
-
No. CAS 53774-63-3
-
Appearance Solid
-
Peso molecular 187.24
-
Fòrmula C8H17N3O2
-
Color White to off-white
-
SMILES
N[C@@H](CCCCNC(C)=N)C(O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Biomed Eng
Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. [Abstract]2023 Mar;7(3):281-297. PMID: 36941352 -
Nat Commun
Host glutathione is required for Rickettsia parkeri cell division and intracellular survival. [Abstract]2025 Jul 1;16(1):5547. PMID: 40593553 -
J Adv Res
iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation. [Abstract]2023 Jan:43:175-186. PMID: 36585107
L-NIL purchased from MedChemExpress. Usage Cited in: J Adv Res. 2023 Jan:43:175-186. [Abstract]
Inhibiting iNOS with L-NIL (10 μM) blunted the adverse effect of iNOS expression in cardiomyocytes.
-
Sci Transl Med
SARS-CoV-2 induces neutrophil degranulation and differentiation into myeloid-derived suppressor cells associated with severe COVID-19. [Abstract]2025 May 21;17(799):eadn7527. PMID: 40397714 -
Cancer Lett
Inducible nitric oxide synthase (iNOS)-activated Cxcr2 signaling in myeloid cells promotes TGFβ-dependent squamous cell carcinoma lung metastasis. [Abstract]2023 Aug 28:570:216330. PMID: 37524225 -
Free Radic Biol Med
Cigarette smoke induces the ROS accumulation and iNOS activation through deactivation of Nrf-2/SIRT3 axis to mediate the human bronchial epithelium ferroptosis. [Abstract]2023 May 1:200:73-86. PMID: 36871899 -
J Agric Food Chem
Quercetin Inhibits Neuronal Pyroptosis and Ferroptosis by Modulating Microglial M1/M2 Polarization in Atherosclerosis. [Abstract]2024 May 29;72(21):12156-12170. PMID: 38755521 -
Exp Eye Res
2024 Jun:243:109886. PMID: 38583755 -
Biochem Biophys Res Commun
Exploring the role of iNOS in HFpEF-Related myocardial fibrosis: Involvement of PTEN-PI3K/AKT signaling pathway. [Abstract]2024 Nov 19:734:150589. PMID: 39245028 -
bioRxiv
A genetic screen identifies O-antigen as essential for Rickettsia parkeri survival in macrophages by protecting from inflammasomes and interferon-stimulated genes. [Abstract]2026 Jun 13:2026.06.12.731980. PMID: 42327330
Solvente y solubilidad
In Vitro:
H2O : 50 mg/mL (267.04 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (534.07 mM); Clear solution; Need ultrasonic
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Consuelo Pasten, et al. l-NIL prevents the ischemia and reperfusion injury involving TLR-4, GST, clusterin, and NFAT-5 in mice. Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F624-F634. [Content Brief]
[2]. Sharon Angela Tanuseputero, et al. Intravenous Arginine Administration Downregulates NLRP3 Inflammasome Activity and Attenuates Acute Kidney Injury in Mice with Polymicrobial Sepsis. Mediators Inflamm. 2020 May 11;2020:3201635. [Content Brief]
[3]. Moore WM, et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem. 1994 Nov 11;37(23):3886-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 5.3407 mL | 26.7037 mL | 53.4074 mL | 133.5185 mL |
| 5 mM | 1.0681 mL | 5.3407 mL | 10.6815 mL | 26.7037 mL | |
| 10 mM | 0.5341 mL | 2.6704 mL | 5.3407 mL | 13.3518 mL | |
| 15 mM | 0.3560 mL | 1.7802 mL | 3.5605 mL | 8.9012 mL | |
| 20 mM | 0.2670 mL | 1.3352 mL | 2.6704 mL | 6.6759 mL | |
| 25 mM | 0.2136 mL | 1.0681 mL | 2.1363 mL | 5.3407 mL | |
| 30 mM | 0.1780 mL | 0.8901 mL | 1.7802 mL | 4.4506 mL | |
| 40 mM | 0.1335 mL | 0.6676 mL | 1.3352 mL | 3.3380 mL | |
| 50 mM | 0.1068 mL | 0.5341 mL | 1.0681 mL | 2.6704 mL | |
| 60 mM | 0.0890 mL | 0.4451 mL | 0.8901 mL | 2.2253 mL | |
| 80 mM | 0.0668 mL | 0.3338 mL | 0.6676 mL | 1.6690 mL | |
| 100 mM | 0.0534 mL | 0.2670 mL | 0.5341 mL | 1.3352 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
L-NIL Related Classifications
HY-12116 Related Classifications
Powered by Bioz